-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
4D Molecular Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2019 to Q3 2025.
- 4D Molecular Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$56.9M, a 29.7% decline year-over-year.
- 4D Molecular Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$209M, a 45.8% decline year-over-year.
- 4D Molecular Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$161M, a 59.5% decline from 2023.
- 4D Molecular Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$101M, a 6.19% increase from 2022.
- 4D Molecular Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$107M, a 50.7% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)